Bergen, Norway 20 December 2021

Development and preparations for first-in-human pilot study is on track as
Lifecare successfully has manufactured nanogranular tunneling strain (NTR)
sensors on the prototype Sencell electrodes at the new Lifecare NanoBioSensors
laboratory. The manufacturing of NTR sensors is a major technical achievement
for Lifecare.

Read more in the Lifecare December newsletter:
 
https://mailchi.mp/04dca0cc9477/newsletter-december-2021

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The Company's patented technology also has the
potential for use in various biomarkers. Lifecare AS is listed on Euronext
Growth (LIFE).

Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no,
+47 40 05 90 40 

This stock exchange announcement was published by Kine Hereid, Investor
Relations at Lifecare AS, on 20.12.21 at 14:10 CET.